A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Part of paid clinical trials in Tempe, Arizona.
- Sponsor
- Tesaro, Inc.
- Study ID
- NCT02655016
- Phase
- PHASE3
- Status
- Active Not Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Niraparib — DRUGNiraparib will be administered.
- Placebo — DRUGPlacebo will be administered.
Study Details
This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.
Key Dates
- Start date
- Jul 11, 2016
- Status verified
- Feb 2026
- Primary completion
- May 17, 2019
- Completion
- May 29, 2026
Study Design
- Enrollment
- 733 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Participants receiving Niraparib
- Placebo Comparator: Participants receiving Placebo
Primary Outcome Measure
Progression Free Survival [ Time Frame: Up to 34 months ]
Locations (47)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| GSK Investigational Site | Tempe | Arizona | 85284 | - |
| GSK Investigational Site | Tucson | Arizona | 85710 | - |
| GSK Investigational Site | Tucson | Arizona | 85724 | - |
| GSK Investigational Site | San Francisco | California | 94115 | - |
| GSK Investigational Site | San Francisco | California | 94118 | - |
| GSK Investigational Site | Santa Rosa | California | 95403 | - |
| GSK Investigational Site | New Haven | Connecticut | 06510 | - |
| GSK Investigational Site | Jacksonville | Florida | 32224 | - |
| GSK Investigational Site | Miami | Florida | 33136 | - |
| GSK Investigational Site | Atlanta | Georgia | 30342 | - |
| GSK Investigational Site | Savannah | Georgia | 31404 | - |
| GSK Investigational Site | Geneva | Illinois | 60555 | - |
| GSK Investigational Site | Indianapolis | Indiana | 46237 | - |
| GSK Investigational Site | Indianapolis | Indiana | 46260 | - |
| GSK Investigational Site | Iowa City | Iowa | 52242 | - |
| GSK Investigational Site | Covington | Louisiana | 70433 | - |
| GSK Investigational Site | New Orleans | Louisiana | 70121 | - |
| GSK Investigational Site | Baltimore | Maryland | 21215-5271 | - |
| GSK Investigational Site | Rockville | Maryland | 20910 | - |
| GSK Investigational Site | Burlington | Massachusetts | 01805 | - |
| GSK Investigational Site | Grand Rapids | Michigan | 49503 | - |
| GSK Investigational Site | Minneapolis | Minnesota | 55433 | - |
| GSK Investigational Site | Springfield | Missouri | 97477 | - |
| GSK Investigational Site | Neptune City | New Jersey | 07753 | - |
| GSK Investigational Site | Harrison | New York | 10604 | - |
| GSK Investigational Site | Mineola | New York | 11501 | - |
| GSK Investigational Site | New York | New York | 10016 | - |
| GSK Investigational Site | Rochester | New York | 14620 | - |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599-7570 | - |
| GSK Investigational Site | Wilmington | North Carolina | 28401 | - |
| GSK Investigational Site | Columbus | Ohio | 43210 | - |
| GSK Investigational Site | Oklahoma City | Oklahoma | 73104 | - |
| GSK Investigational Site | Tulsa | Oklahoma | 74146 | - |
| GSK Investigational Site | Portland | Oregon | 97210 | - |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19104 | - |
| GSK Investigational Site | Willow Grove | Pennsylvania | 19090 | - |
| GSK Investigational Site | Providence | Rhode Island | 02905 | - |
| GSK Investigational Site | Charleston | South Carolina | 29425 | - |
| GSK Investigational Site | Sioux Falls | South Dakota | 57105 | - |
| GSK Investigational Site | Fort Worth | Texas | 76104 | - |
| GSK Investigational Site | The Woodlands | Texas | 77380 | - |
| GSK Investigational Site | Tyler | Texas | 75701 | - |
| GSK Investigational Site | Salt Lake City | Utah | 84112 | - |
| GSK Investigational Site | Kennewick | Washington | 99336 | - |
| GSK Investigational Site | Seattle | Washington | 98104 | - |
| GSK Investigational Site | Spokane | Washington | 99202 | - |
| GSK Investigational Site | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Tempe, AZ
By condition
By specialty
Related Studies
- A Study of Sigvotatug Vedotin in Advanced Solid TumorsPHASE1 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Anchorage, Alaska
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyPHASE2 · Recruiting · GlaxoSmithKline · Tucson, Arizona
- Developing a Test of Uterine Lavage for the Detection of Ovarian CancerRecruiting · Massachusetts General Hospital · Little Rock, Arkansas
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Bristol-Myers Squibb · Clovis, California